Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Masimo Co. (NASDAQ:MASI) have received an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $164.20.

MASI has been the subject of several research analyst reports. BTIG Research reiterated a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. UBS Group lifted their price objective on Masimo from $172.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Stifel Nicolaus lifted their price objective on Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, BidaskClub downgraded Masimo from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 6th.

MASI traded up $0.13 during trading on Friday, reaching $151.63. The company had a trading volume of 5,517 shares, compared to its average volume of 318,725. The stock has a market cap of $8.19 billion, a P/E ratio of 50.08, a PEG ratio of 2.38 and a beta of 1.22. The business has a 50 day simple moving average of $152.01 and a 200-day simple moving average of $142.73. Masimo has a 52 week low of $98.23 and a 52 week high of $160.25.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. The company had revenue of $229.60 million during the quarter, compared to the consensus estimate of $222.46 million. Masimo had a return on equity of 17.82% and a net margin of 22.15%. Masimo’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the company earned $0.73 earnings per share. On average, equities research analysts expect that Masimo will post 3.15 earnings per share for the current fiscal year.

In other news, EVP Yongsam Lee sold 2,371 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $145.90, for a total transaction of $345,928.90. Following the sale, the executive vice president now owns 74,301 shares in the company, valued at $10,840,515.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joe E. Kiani sold 18,437 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $160.02, for a total value of $2,950,288.74. Following the sale, the chief executive officer now owns 157,678 shares in the company, valued at approximately $25,231,633.56. The disclosure for this sale can be found here. Insiders sold 209,062 shares of company stock worth $31,927,074 in the last quarter. 11.50% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the company. Capital Investment Advisory Services LLC acquired a new position in Masimo in the second quarter valued at approximately $25,000. Financial Gravity Wealth Inc. acquired a new position in Masimo in the second quarter valued at approximately $31,000. Pearl River Capital LLC acquired a new position in Masimo in the second quarter valued at approximately $37,000. Private Capital Group LLC lifted its holdings in Masimo by 92.1% in the second quarter. Private Capital Group LLC now owns 340 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 163 shares during the period. Finally, FinTrust Capital Advisors LLC acquired a new position in shares of Masimo during the 1st quarter worth approximately $61,000. Institutional investors and hedge funds own 83.07% of the company’s stock.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Story: What is a Special Dividend?

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit